


PRODUCT INFORMATION



Fludarabine Phosphate

Item No. 14251

CAS Registry No.: 75607-67-9
Formal Name: 2-fluoro-9-(5-O-phosphono-β-D-arabinofuranosyl)-9H-purin-6-amine
Synonyms: F-ara-AMP, NSC 312887, NSC 328002
MF: C₁₀H₁₃FN₅O₇P
FW: 365.2
Purity: ≥95%
UV/Vis.: λ_{max}: 261 nm
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥2 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Fludarabine phosphate is supplied as a crystalline solid. Aqueous solutions of fludarabine phosphate can be prepared by directly dissolving the crystalline solid in aqueous buffers. The solubility of fludarabine phosphate in PBS, pH 7.2, is approximately 3 mg/ml. We do not recommend storing the aqueous solution for more than one day.

Description

Fludarabine phosphate is an injectable form of fludarabine (Item No. 14128).¹ Fludarabine is an adenosine deaminase resistant analog of 9-β-D-arabinofuranosyladenine (ara-A) that disrupts ribonucleotide reductase and DNA polymerase in blood cells. It exhibits antiproliferative activity (IC₅₀ = 1.54 μM in an RPMI-8226 myeloma cell line) and triggers apoptosis by increasing Bax and decreasing Bid, XIAP, and survivin expression.^{2,3} Fludarabine is effective in a number of animal tumor systems including LI210 leukemia, CD8F mammary adenocarcinoma, P388 leukemia, and human LX-1 lung tumor xenograft and displays anti-cancer activity against human hematological malignancies *in vivo*.^{1,4-5}

References

1. Spriggs, D.R., Stopa, E., Mayer, R.J., *et al.* Fludarabine phosphate (NSC 312878) infusions for the treatment of acute leukemia: Phase I and neuropathological study. *Cancer Res.* **46**, 5953-5958 (1986).
2. Meng, H., Yang, C., Ni, W., *et al.* Antitumor activity of fludarabine against human multiple myeloma *in vitro* and *in vivo*. *Eur. J. Haematol.* **79**(6), 486-493 (2007).
3. Bellosillo, B., Villamor, N., Colomer, D., *et al.* *In vitro* evaluation of fludarabine in combination with cyclophosphamide and/or mitoxantrone in B-cell chronic lymphocytic leukemia. *Blood* **94**(8), 2836-2843 (1999).
4. Tournilhac, O., Cazin, B., Leprêtre, S., *et al.* Impact of frontline fludarabine and cyclophosphamide combined treatment on peripheral blood stem cell mobilization in B-cell chronic lymphocytic leukemia. *Blood* **103**(1), 363-365 (2004).
5. Rai, K.R., Peterson, B.L., Appelbaum, F.R., *et al.* Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. *N. Engl. J. Med.* **343**(24), 1750-1757 (2000).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 05/17/2017

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM